Medications

Lanadelumab in hereditary angioedema: Added benefit not proven

The monoclonal antibody lanadelumab has been approved in Europe since 2015 as a long-term prophylaxis to prevent attacks of hereditary angioedema. Since this is a rare disease, the Federal Joint Committee (G-BA) initially ...

Medical economics

Singapore gets shot in the arm from global drug demand

Scientists in protective clothing work in a high-tech laboratory at a pharmaceutical plant in Singapore, whose coronavirus-hit economy has received a shot in the arm from robust global drug demand.

page 4 from 20